SCHEMBL22164678

SCHEMBL22164678

CCc1oc2ccccc2c1CN1CCN2C(=O)CN(Cc3ccc(-c4ccccc4)cc3)C(=O)C2C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM2 Q14416 1/20 0.37
▸ ENPP2 Q13822 1/20 0.36
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ TLR9 Q9NR96 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ THRB P10828 1/20 0.34
▸ SIGMAR1 Q99720 1/20 0.34
▸ ACHE P22303 1/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23967357 0.95 SIGMAR1 (0.39) KMT2AMEN1HTR1ALMNAALDH1A1
SCHEMBL22164696 0.92 LMNA (0.42) KMT2AMEN1HTR1ALMNAALDH1A1
SCHEMBL23967353 0.92 MAPT (0.37) KMT2AMEN1HTR1ALMNAALDH1A1
SCHEMBL22173770 0.91 LMNA (0.38) HTR1ALMNAALDH1A1MAPTKDM4E
SCHEMBL22164683 0.91 HTR1A (0.35) KMT2AMEN1HTR1ALMNAALDH1A1
SCHEMBL22164777 0.89 LMNA (0.35) KMT2AMEN1HTR1ALMNAALDH1A1
SCHEMBL22165535 0.89 VKORC1 (0.38) HTR1ALMNAALDH1A1MAPTKDM4E
SCHEMBL22165377 0.88 DRD4 (0.37) KMT2AHTR1AALDH1A1KDM4ETDP1
SCHEMBL23967419 0.88 HTR1A (0.39) KMT2AMEN1HTR1ALMNAALDH1A1
SCHEMBL22165531 0.87 ABCB1 (0.40) KMT2AHTR1AALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12139491-B2 Diketopiperazine derivatives as calcium ATPase inhibitor for enhancing anticancer activity HOLOSMEDIC (KR) 2024-11-12 — — US disclosed
EP-3903786-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR ENHANCING ANTICANCER ACTIVITY Holosmedic (KR) 2021-11-03 — — EP disclosed
WO-2020139044-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR ENHANCING ANTICANCER ACTIVITY 홀로스메딕 주식회사 2020-07-02 — — WO disclosed
WO-2020139044-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR ENHANCING ANTICANCER ACTIVITY 홀로스메딕 주식회사 2020-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12139491-B2 Diketopiperazine derivatives as calcium ATPase inhibitor for enhancing anticancer activity ATP1A1, ATP1B1, ATP1B2 GRM2 4103/4885ENPP2 1892/4885KMT2A 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback